Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia

(2015) Wolfgang Warsch et al.   Oncotarget

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

(2014) E. Traer et al.   BLOOD

BCR-ABL-Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients

(2014) A. Levescot et al.   CANCER RESEARCH

NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

(2014) B. Sanchez-Sanchez et al.   CLINICAL CANCER RESEARCH

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

(2013) E. Bolton-Gillespie et al.   BLOOD

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling

(2013) B. Zhang et al.   BLOOD

Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy

(2013) V. Nogueira et al.   CLINICAL CANCER RESEARCH

Modulation of oxidative stress as an anticancer strategy

(2013) Chiara Gorrini et al.   NATURE REVIEWS DRUG DISCOVERY

Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells

(2013) Ahmad Hamad et al.   Stem Cells International

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation

(2012) Krzysztof Flis et al.   LEUKEMIA & LYMPHOMA

Imatinib and Nilotinib inhibit Bcr–Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox

(2012) William D. Landry et al.   LEUKEMIA RESEARCH

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Do reactive oxygen species play a role in myeloid leukemias?

(2011) P. S. Hole et al.   BLOOD

The anticancer effects of chaetocin are independent of programmed cell death and hypoxia and are associated with inhibition of endothelial cell proliferation

(2011) C R Isham et al.   BRITISH JOURNAL OF CANCER

Development of an Effective Therapy for Chronic Myelogenous Leukemia

(2011) David W. Woessner et al.   CANCER JOURNAL

Selective killing of cancer cells by a small molecule targeting the stress response to ROS

(2011) Lakshmi Raj et al.   NATURE

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML

(2010) Rajesh R. Nair et al.   BIOCHEMICAL PHARMACOLOGY

Molecular pathways to CML stem cells

(2010) Kristen N. Rice et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

(2010) D K Hiwase et al.   LEUKEMIA

The Anticancer Agent Chaetocin Is a Competitive Substrate and Inhibitor of Thioredoxin Reductase

(2008) Jennifer D. Tibodeau et al.   ANTIOXIDANTS & REDOX SIGNALING

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism

(2008) H Zhang et al.   LEUKEMIA

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

(2008) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS